PRLD compared with TRAW: revenue, margins and what each company keeps, and the suppliers and customers both name

PRLDPrelude Therapeutics Inc

Mkt capRevenueRevenue

TRAWTraws Pharma, Inc.

Mkt capRevenueRevenue

Compare

PRLDPrelude Therapeutics Inc

TRAWTraws Pharma, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

PRLD1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±17.9%▲+10.14%×0.56

TRAW1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−5.43%—

= impliedPRLD realized, solidTRAW realized, hatchedOne scale, both sides: full bar = 18%× = |realized| ÷ impliedSource: market data

PRLDPrelude Therapeutics Inc

3.84· pre 3.84· delayed

Mkt cap$306.4MRevenue$6MQ2 FY26Revenue—

TRAWTraws Pharma, Inc.

0.30· pre 0.30· delayed

Pre-marketNov 2 '26delayed

Mkt cap$4.5MRevenue$3MQ2 FY25Revenue$3MFY24

Compare

Pre-marketNov 2 '26delayed

PRLDPrelude Therapeutics Inc

TRAWTraws Pharma, Inc.

3.84pre 3.84delayed

Price

0.30pre 0.30delayed

$306.4M

Mkt cap

$4.5M

Q2 FY26$6M

Revenue

$3MQ2 FY25

—

Revenue

$3MFY24

PRLD3.84vsTRAW0.30Pre-marketNov 2 '26delayed